(Q35076601)

6 August 2017

title

Review of ibandronate in the treatment of osteoporosis (English)

1 reference

6 August 2017

0 references

2

Pierre D Delmas

1 reference

6 August 2017

1

Roland D Chapurlat

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 March 2003

1 reference

Expert Opinion on Pharmacotherapy

6 August 2017

published in

1 reference

6 August 2017

volume

4

1 reference

6 August 2017

issue

3

1 reference

6 August 2017

page(s)

391-396

1 reference

Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.3.391

Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.3.391

Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.3.391

Intravenous zoledronic acid in postmenopausal women with low bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.3.391

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.3.391

Lifelong administration of high doses of ibandronate increases bone mass and maintains bone quality of lumbar vertebrae in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.3.391

The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.3.391

Association between pharmacokinetics of oral ibandronate and clinical response in bone mass and bone turnover in women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.3.391

Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.3.391

21 January 2018

Identifiers

DOI

10.1517/14656566.4.3.391

1 reference

6 August 2017

1 reference